Drug Development ProgressThe IND resubmission potentially allows the Phase 2/3 trial to begin soon, indicating progress in the company's drug development.
Financial SupportCoya would be eligible to receive milestone payments totaling $8.4M from strategic partner, Dr. Reddy’s Laboratories, upon IND acceptance and first patient dosing of COYA-302 in ALS.
Investor InterestThe potential impact of the COYA-303 program, which uses a combination of low dose IL2 and a GLP-1 receptor agonist, could draw investor interest due to its promise in treating AD patients.